Keratoacanthomas have an immunosuppressive cytokine environment of increased IL-10 and decreased GM-CSF compared to squamous cell carcinomas by Lowes, M A et al.
The natural history of keratoacanthomas (KAs) is rapid growth
followed by spontaneous involution, rarely invading or metasta-
sizing, while squamous cell carcinomas (SCCs) show a variably
progressive behaviour with local invasion and metastatic spread.
There are also classical histological features distinguishing both
these tumours. The process of KA growth and regression can be
histologically documented. Mature KAs tend to have a character-
istic architecture of a crateriform keratin-filled tumour, with the
epidermis overhanging the sides forming a ‘buttress’, while SCCs
show variable differentiation, anaplasia, pleomorphism, dysker-
atosis and abnormal mitoses (Schwartz and Stoll, 1993; Schwartz,
1994). However, it is not possible to distinguish between KA and
SCC on the basis of any one single clinical or histological feature
(Schwartz, 1994), and misdiagnosis between these tumours is
not uncommon. There are patterns of expression of various
histopathological features, including ultrastructural appearance,
cellular antigen and differentiation marker expression, and DNA
studies, which can aid in accurate diagnosis.
The relationship between KAs and SCCs is still controversial.
Suggestions include distinct entities, KAs may be a benign tumour
in a spectrum with the more aggressive SCC at the malignant end,
or KAs may represent a ‘self-healing’ or regressing form of SCC
(Le Boit, 1995), much like actinic keratoses which also frequently
regress spontaneously (Marks et al, 1986). The mechanism of KA
resolution has also not been determined. Proposals include natural
involution mirroring the hair cycle (Ghadially and Ghadially,
1993), rapid terminal differentiation secondary to immune
stimulation (Prehn, 1996), or an activated immunological response
directly destroying the tumour (Patel et al, 1994). Genetic events
may also play a role in spontaneous KA resolution.
A recent study found the following features of regression were
increased in KAs compared to SCCs: presence and degree of
apoptosis, presence and degree of tumour degeneration, degree of
stromal inflammatory infiltrate, presence of peritumoural neovas-
cularization, and the presence of peritumoural fibrosis (Patel et al,
1994). The intratumoural inflammatory infiltrate in KAs consisted
of significantly greater numbers of CD4+ T-cells, and increased
markers of activation on tumour cells (CD36 and ICAM-1) and
T-cells (interleukin (IL)-2 receptor, IL-2R). CD4+ T-cells have
been similarly implicated in regression of melanomas (Tefany
et al, 1991) and basal cell carcinomas (BCCs) (Hunt et al, 1994).
In this study, the cytokine profile of 12 KAs and eight SCCs was
determined to provide an insight into the possible mechanism of
spontaneous regression of KAs. The results indicate that the KAs
resolve in an immunosuppressive cytokine microenvironment.
MATERIALS AND METHODS
Tumour collection
Lesions suspected of being a KA or SCC were collected from
February 1994 to February 1996, from the Dermatology
Outpatient Department and plastic surgery inpatients at Royal
Prince Alfred Hospital. Specimens were also collected from
Keratoacanthomas have an immunosuppressive
cytokine environment of increased IL-10 and decreased
GM-CSF compared to squamous cell carcinomas
MA Lowes1, GA Bishop2, BE Cooke3, RStC Barnetson1 and GM Halliday1
1Department of Medicine (Dermatology), University of Sydney at Royal Prince Alfred Hospital, Room W210, Blackburn Building D06, Sydney, NSW 2006,
Australia; 2Liver Immunobiology Unit, Centenary Institute of Cancer Medicine and Cell Biology, Sydney, NSW, Australia; 3Anatomical Pathology, Prince of Wales
Hospital, Sydney, NSW, Australia
Summary To investigate the relationship between keratoacanthoma (KA) and squamous cell carcinoma (SCC), cytokine mRNA in 12 KA and
eight SCC were compared. Normal skin was also studied. Reverse transcription polymerase chain reaction (RT-PCR) was used to quantitate
mRNA in each sample utilizing DNA standards. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control, and
CD3d as an indication of the T-cell infiltrate. KAs showed a significant increase in interleukin (IL)-10, and a decrease in granulocyte
macrophage colony-stimulating factor (GM-CSF) mRNA compared to SCCs. CD3d mRNA was also increased in the KAs. There was no
difference between KAs and SCCs in expression of lymphotoxin-a, IL-2, interferon-g (IFN-g), IL-13, transforming growth factor-b (TGF-b), or
the pro-inflammatory cytokines IL-8 or tumour necrosis factor-a (TNF-a). These results indicate that KAs spontaneously resolve in an
immunosuppressive environment. KAs grow rapidly over a period of weeks and then involute. It is possible that a suppressed immune
response enables unimpeded growth and that the KA cells rapidly undergo the finite number of cell divisions of which they are capable, and
then die without reaching immortality.
Keywords: skin cancer; tumour regression; tumour immunology; tumour development
1501
British Journal of Cancer (1999) 80(10), 1501–1505
© 1999 Cancer Research Campaign
Article no. bjoc.1999.0552
Received 20 October 1998
Revised 2 February 1999
Accepted 9 February 1999
Correspondence to: GM Hallidayprivate dermatologists’ rooms. Tumours were not collected for this
study if the lesion was recurrent, or if the patient was an organ
transplantation recipient, immunosuppressed, or had a history of
prior chemotherapy. Ulcerated lesions were not included unless
the tumour was large and the area of ulceration could be avoided.
In all cases, informed consent was obtained as per the guidelines
of the Central Sydney Area Health Service Human Ethics
Committee. A 3–6 mm punch biopsy was obtained from the lesion
as soon as possible after surgery, snap-frozen, and stored in liquid
nitrogen until required. The remainder of the tumour was
formalin-fixed and paraffin-embedded for routine histological
examination.
Normal skin collection
Samples of normal human skin were obtained during cosmetic
breast reduction surgery, from healthy volunteers, or from the ends
of ellipses during removal of clinically benign naevi at Royal
Prince Alfred Hospital.
Classification of KAs and SCCs
Paraffin sections were examined to classify the tumours as KA or
SCC based on the histological criteria (Schwartz and Stoll, 1993;
Schwartz, 1994). KAs are symmetrical tumours with a character-
istic keratin-filled crater with a buttress, showing proliferation at
the sides and base only. There are few mitotic figures at the base,
and large homogeneous eosinophilic glassy cells, with minimal
atypia. SCCs are evident as columns or clumps of tumour cells
invading the dermis, and proliferation is seen throughout the
lesion. There are frequent abnormal mitoses, varying degrees of
differentiation and the cells may be anaplastic and pleomorphic.
There may be single cell keratosis, horn pearl formation and
dyskeratosis.
Total RNA extraction and complementary DNA (cDNA)
synthesis
Total RNA was prepared by acid guanidinium thiocyanate–
phenol–chloroform extraction (Chomczynski and Sacchi, 1987)
as previously described (Lowes et al, 1997). One microgram of
biopsy RNA was reverse transcribed using Superscript RNAase
H– enzyme kit (Gibco BRL, Gaithersberg, MD, USA) with
Oligo dT (Boehringer, Sydney, NSW, Australia). A negative
control consisted of a cDNA synthesis reaction omitting the
reverse transcriptase enzyme (minus RT control). cDNA synthesis
was performed in duplicate, termed cDNA1 and cDNA2.
Non-competitive quantitative PCR
Polymerase chain reactions (PCR) were performed as previously
described (Lowes et al, 1997). Each primer pair was optimized for
magnesium chloride and Taq DNA polymerase concentrations and
PCR amplification conditions. The PCR quantitation method of
Dallman et al (1991) was modified to include external cytokine
standards. Aliquots of 4.5 ml were removed from the samples and
standards at each cycle, for most cytokines from cycle 28 onward.
Aliquots were transferred to Hybond N+ nylon membrane
(Amersham, Little Chalfont, UK) using a dot-blot vacuum appa-
ratus (Bio-Rad, Richmond, CA, USA) and membranes hybridized
with a ATP-g-33P (DuPont, deNemours, France) end-labelled
hybridization primer. Washed membranes were exposed to a phos-
phor imaging plate (Fuji Photo Film, Tokyo, Japan) and scanned
on a Fujix Bio-imaging analyser BAS 1000 (Fujix, Tokyo, Japan)
and the radioactivity in each dot was integrated. The number of
molecules of cytokine cDNA for each specimen was calculated by
the use of a standard curve prepared from the known number of
molecules included in each run, as previously described (Bishop
et al, 1997; Lowes et al, 1997). The reproducibility of the RT-PCR
reaction was assessed by correlation of the results for cDNA1 and
cDNA2 by linear regression analysis.
These results were averaged to give a final estimate of the
number of molecules of cytokine cDNA. This was divided by the
number of molecules of the internal control, glyceraldehyde-
3-phosphate dehydrogenase (GAPDH), for the sample and multi-
plied by 106.
The oligonucleotide cytokine amplification and hybridization
primers used for GAPPH, IL-2, IL-8, IL-10, interferon (IFN)-g,
tumour necrosis factor (TNF)-a, lymphotoxin-a, and transform-
ing growth factor (TGF)-b1 have been published (Lowes et al,
1997), as have granulocyte-macrophage colony-stimulating factor
(GM-CSF) (Ehlers and Smith, 1991) and CD3d (Yamamura et al,
1991).
Statistical analysis
Non-parametric tests were used to test for significant differences
as the data were not normally distributed. The Spearman rank
correlation coefficient was used for linear regression analysis of
cDNA syntheses, and the Mann–Whitney U-test used for tumour
group analysis. A P-value of <0.05 was regarded as significant.
RESULTS
Characteristics of KAs and SCCs used for RT-PCR
Patients from whom tumours were collected were all over 50 years
of age, and the average age (± standard deviation) of patients from
both groups was very similar, 73.8 (±13.9) years for KAs and 73.4
(±11.6) years for SCCs. The sex distribution was equal in the KA
group, and SCCs were collected from more females than males
(M:F, 3:5). The average time to presentation in the KA group
(8.8 ± 6.9 weeks) was statistically lower than the SCC group
(13.6  ± 19.6 months) (Mann–Whitney U-test, P < 0.05). Tumours
were predominantly located on sun-exposed sites: none were on
the trunk and the only exception was an SCC located on the thigh.
The majority of KAs were on the upper limbs (66.7%), while the
majority of the SCCs were on the head and neck (62.5%).
Cytokine mRNA analysis
cDNA products were of predicted size by ethidium bromide-
stained gel electrophoresis. Minus RT controls were negative for
all cytokines. The quantitative method described here showed
good reproducibility, with high correlations between cDNA 1 and
cDNA 2 (P < 0.0001–0.05) for all cytokines.
GAPDH
GAPDH was used as a positive internal control to correct for
variations between specimens in the amount, quality and stability
of mRNA. There was no statistical difference in the number of
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KAs and normal skin. The KAs contained a median number of
molecules of GAPDH of 5.89 ´ 105 (range 1.14 ´ 105–2.39 ´ 106),
the SCCs had a median of 2.51 ´ 106 (range 3.10 ´ 105–
4.63  ´ 106), and normal skin had a median 4.60 ´ 105 (range
1.34 ´ 105–1.23 ´ 106).
CD3d
The ratio of the number of molecules of CD3d mRNA per 106
molecules of GAPDH mRNA is shown in Figure 1. KAs contained
a median of 3.09 ´ 104 (range 1.71 ´ 104–2.31  ´ 105), which
was significantly higher than the SCCs which had a median of
1.55 ´ 104 (range 6.24 ´ 103–5.32 ´ 104) (P < 0.05), but not signifi-
cantly different from the normal skin which had a median of
1.58  ´ 104 (range 4.81 ´ 103–5.24 ´ 104).
IL-10 was elevated in KAs
The ratio of the number of molecules of IL-10 mRNA per 106
molecules of GAPDH mRNA is shown in Figure 2. The median
for IL-10 in the KAs was 3.33 ´ 104 (range 1.61 ´ 104–1.03 ´ 105),
which was significantly elevated in comparison to the SCCs,
which had a median of 1.83 ´ 104 (range 6.42 ´ 103–2.30 ´ 104)
(P < 0.005). The median number of molecules of IL-10 in normal
skin was 1.24 ´ 104 (range 7.27 ´ 103–5.11 ´ 104) which was not
significantly different to the KA group.
GM-CSF was reduced in KAs
The ratio of the number of molecules of GM-CSF mRNA per
106 molecules of GAPDH mRNA is shown in Figure 3.
GM-CSF/GAPDH was significantly less in the KAs which had
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Figure 1 CD3d mRNA was elevated in KAs compared to SCCs. Ratio of
number of molecules of CD3d mRNA per 106 molecules GAPDH mRNA. KA
was significantly different to SCC, P < 0.05. KA compared to normal skin was
not significantly different (Mann–Whitney U-test). Each point represents a
single sample
Figure 2 IL-10 mRNA was elevated in KAs compared to SCCs. Ratio of
number of molecules of IL-10 mRNA per 106 molecules GAPDH mRNA. KA
was significantly different to SCC, P < 0.005. KA compared to normal skin
was not significantly different (Mann–Whitney U-test). Each point represents
a single sample
Figure 3 GM-CSF mRNA was reduced in KAs compared to SCCs. Ratio of
number of molecules of GM-CSF mRNA per 106 molecules GAPDH mRNA.
KA was significantly different to SCC, P < 0.05. KA compared to normal skin
was not significantly different (Mann–Whitney U-test). Each point represents
a single sample
Table 1 Cytokines and growth factors which did not differ between KAs and SCCs
Cytokinea KAb SCCb Normal skinb
IL-2 58 (12–99) 70 (11–132) 76 (36–86)
LT-a 539 (125–1.06 ´ 103) 693 (110–899) 935 (356–2.02 ´ 103)
IFN-g 3.19 ´ 104 (4.71 ´ 103–4.66 ´ 105) 2.42 ´ 104 (1.18 ´ 104–4.57 ´ 104) 8.39 ´ 103 (3.67 ´ 103–7.51 ´ 104)
IL-13 4 (0–20) 3 (0–13) 19 (0–102)
IL-8 4.67 ´ 103 (1.53 ´ 103–1.12 ´ 105) 3.82 ´ 103 (1.54 ´ 103–9.37 ´ 103) 1.03 ´ 103 (119–8.23 ´ 103)
TNF-a 80 (0–1.74 ´ 103) 69 (25–103) 168 (68–591)
TGF-b 695 (0–1.75 ´ 104) 1.31 ´ 103 (304–6.38 ´ 103) 310 (0–1.04 ´ 103)
aNo significant differences between KAs and SCCs for any cytokine, or between KAs and normal skin (Mann–Whitney U-test). bMedian ratio of the number of
molecules of cytokine mRNA per 106 molecules of GAPDH (range) in KAs (n = 12), SCCs (n = 8) and normal skin (n = 4).a median of 54 (range 0–348), compared to the SCC group which
had a median of 133 (range 26–618) (P < 0.05). Normal skin had a
median of 87 (range 46–141) for GM-CSF which was not signifi-
cantly different to the KAs.
Cytokines and growth factors which did not show a
difference between KAs and SCCs
None of the other cytokines or growth factors investigated,
lymphotoxin-a, IL-2, IFN-g, IL-13, TGF-b, IL-8, or TNF-a
showed significant differences between the KAs and SCCs, or
between KAs and normal skin (Table 1).
Correlation of cytokine mRNA with CD3d mRNA
There were positive Spearman rank correlations between the
GAPDH-corrected number of molecules of CD3d for each tumour
and IL-10 (P < 0.005), IFN-g (P < 0.0005), IL-8 (P < 0.05), and
TNF-a (P < 0.001). IL-13 showed a negative correlation with
CD3d (P < 0.05). The results for GM-CSF, the other Th1
cytokines, and TGF-b1 did not show a significant correlation with
CD3d mRNA.
DISCUSSION
The cytokine mRNA profiles in 12 KA and eight SCC were exam-
ined to gain insights into the mechanisms underlying regression or
malignancy of these two tumours respectively. Using a quantita-
tive non-competitive RT-PCR, comparison of the cytokine mRNA
profile of these two tumours has shown an increase in CD3d and
IL-10, and a decrease in GM-CSF, in the KA group compared to
SCCs. The other cytokines analysed did not reveal any significant
differences; these included lymphotoxin-a, IL-2, IFN-g, IL-13,
TGF-b, IL-8 and TNF-a.
CD3d is a component of CD3, which is closely associated with
the T-cell receptor, and its expression was used as a means to
quantitate T-cells in the biopsies. The median result for CD3d in
KAs was significantly greater than in the SCC group and the
magnitude of this difference was approximately twofold. This
is similar to the magnitude of the difference of intratumoural
CD3-positive cells detected immunohistochemically in a group of
KAs compared to SCCs, where the mean number of CD3-positive
cells per mm2 was 78 for KAs and 33 for SCCs (Patel et al, 1994).
The present study found a significant increase in IL-10 in the
KA group compared to the SCCs. This cytokine is usually consid-
ered to be immunosuppressive (Mosmann, 1994), and an impor-
tant factor in the drive toward Th2 type immune responses (Enk
et al, 1993). SCCs have shown greater IL-10 mRNA than sebor-
rhoeic keratoses, a benign cutaneous tumour (Kim et al, 1995).
Four BCC biopsies collected after completion of a course of IFN-
a immunotherapy showed a dramatic decrease in IL-10 mRNA.
However, in an animal sponge model of concomitant tumour
immunity (EMT6 mammary tumour), the IL-10 mRNA was
higher in rejecting lesions compared to the progressing tumours
(Kurt et al, 1995). In murine models, IL-10 is capable of inducing
effective anti-tumoural immune responses in vivo and inhibiting
metastatic growth (Kundu et al, 1996).
GM-CSF has proven anti-tumour activity in mice (Dranoff et al,
1993) and man (Si et al, 1996). The KA group in this study showed
less GM-CSF mRNA than the SCCs. GM-CSF has been shown to
be reduced in other benign compared to malignant skin tumours
(Yamamura et al, 1993). The low level of GM-CSF in the KAs
may impair immune responses to these rapidly proliferating
tumour cells. The absence of differences in the other T-cell or pro-
inflammatory cytokines is also consistent with the conclusion that
the immune system is not very active in the KA tumour.
KAs are very well-differentiated tumours; evidence includes their
clinical, histological and ultrastructural features, and staining
patterns for markers of differentiation. But, although the KA tumour
cells are rapidly proliferating, they do so in a controlled and finite
manner, and are not immortal. The cytokine peritumoural microen-
vironment described in KAs in this study, increased IL-10 and
decreased GM-CSF, is consistent with an immunosuppressive
cytokine milieu. This could impede the development of immune
responses to these tumour cells, so that their growth is not limited by
anti-tumour immunity. In this situation the cells would rapidly
proliferate, but because they do not possess clonal immortality, have
a finite number of proliferations before inevitable death.
This data supports the concept that KAs are a unique premalig-
nant tumour of epidermal cell origin. However, perhaps if there is
a brisk immune response to the KA tumour cells, this may promote
development towards malignancy. There is evidence that the
immune response can aid tumour progression. For example,
macrophages may supply growth factors or activators of angio-
genesis and proteolytic enzymes (Mantovani, 1994). Prehn (1996)
has suggested that, in KAs, the immune infiltrate may be initially
immunostimulatory. These stimulated tumour cells may tend to
terminally differentiate, or grow rapidly before they have achieved
immortality, or the immune infiltrate may change so that it is no
longer stimulatory and the immunodependent KA regresses. The
KAs analysed in the present study were from all phases of tumour
development (proliferative, mature and involuting KAs), and
it would be interesting to determine the nature of the cytokine
environment in these different stages. It is possible that IL-10 may
be primarily elevated during the proliferative phase of growth.
It is interesting to compare the results of the present study with
our recently reported analysis of the cytokine mRNA profile of
spontaneously regressing primary melanomas. These tumours
showed a Th1 pattern (increased IL-2 and lymphotoxin-a) in
comparison to non-regressing primary melanomas (Lowes et al,
1997). This profile suggests melanoma regression may be medi-
ated by secretion of Th1 cytokines, which is in contrast with the
pattern of expression discussed above for KAs. Thus spontaneous
regression of cutaneous tumours may occur by different mecha-
nisms, depending on many factors, including the inherent
tumour properties, tumour antigenicity and peritumoural cytokine
microenvironment.
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